Market News AIOpen the app

Novartis got the green light from the FDA for Cosentyx to treat polymyalgia rheumatica.

TrialRead the original at marketscreener.com
Good for NVS

Novartis can now offer Cosentyx for polymyalgia rheumatica, adding potential patients. It is the first and only anti-IL-17 biologic for this illness, though the source gives no sales estimate.

NVS · Novartis

AI read · Good for NVS

The AI's read

This gives Novartis another group of patients who may be treated with an existing medicine. Cosentyx is described as the first and only anti-IL-17 biologic for this illness, giving it a distinct place. The source gives no sales estimate, but the added use favors the company.

Get alerts for NVS

Follow Novartis (NVS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for NVS
Free on the App Store and Google Play, or on the web.